UTgene Co., Ltd. was founded in 2022 as a platform company specializing in mRNA delivery technology. The company is dedicated to providing high-quality products and professional services to mRNA researchers, empowering the future of mRNA therapeutics.

On the product front, UTgene currently encompasses three core industrial lines: chemistry, mRNA, and LNP. The company offers thousands of innovative cationic lipids, phospholipids, mRNAs, in-vitro transcription kits, and LNP delivery kits.

In the service sector, UTgene offers customized services focusing on chemicals, specialized mRNA, and LNP encapsulation. Particularly in the field of LNP delivery, the company leads in foundational innovation, utilizing combinatorial chemical synthesis to establish a compound library containing thousands of cationic lipids. These compounds can be used for various types of LNP preparation, achieving highly specific targeted delivery of mRNA molecules to organs such as the liver, lungs, and spleen, facilitating the development of mRNA.

Furthermore, UTgene has a comprehensive technical platform covering process scale-up for raw materials and complex formulations, analytical development, GMP production, quality control, and regulatory registration​. The team has accumulated several successful cases of mRNA industrialization, providing clients with an end-to-end solution from mRNA research to industrialization.